Cranford, N.J., March 31, 2026 – Citius Oncology, Inc. (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), has announced a commercial update regarding the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl) for the treatment of cutaneous T-cell lymphoma (CTCL). The company highlighted significant early adoption metrics, indicating a promising trajectory for the product in the oncology market. According to Leonard Mazur, Chairman and CEO of Citius Oncology, the early indicators for LYMPHIR are encouraging, with a notable pace of formulary adoption and broad payer coverage. Approximately 83% of target accounts have either added or are actively progressing LYMPHIR through formulary review, showcasing strong institutional uptake. Furthermore, the company has secured access with around 135 health plans, covering approximately 80% of lives, and has established reimbursement systems without reported denials or prior authorization barriers. The demand for clinical education and in-services is increasing, and initial penetration into community infusion centers is underway. Citius Oncology is also advancing LYMPHIR’s clinical development through collaborations with leading academic centers, evaluating its potential across broader oncology settings. These developments support a disciplined launch trajectory and provide a solid foundation for continued adoption of LYMPHIR.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.